Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rosmantuzumab |
Synonyms | |
Therapy Description |
Rosmantuzumab (OMP-131R10) is a monoclonal antibody that targets R-spondin 3 (RSPO3), which results in decreased pathway activation and may lead to reduced tumor cell proliferation and decreased survival of cancer stem cells (PMID: 32559496). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rosmantuzumab | OMP-131R10 | WNT Inhibitor 16 | Rosmantuzumab (OMP-131R10) is a monoclonal antibody that targets R-spondin 3 (RSPO3), which results in decreased pathway activation and may lead to reduced tumor cell proliferation and decreased survival of cancer stem cells (PMID: 32559496). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02482441 | Phase I | Rosmantuzumab Fluorouracil + Irinotecan + Leucovorin | A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | Completed | USA | 0 |